In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

But medical professionals soon discovered these drugs, including methamphetamines, came with a high potential for addiction. The FDA approved a new central nervous system stimulant called ...

A broad range of nanomedicines is being developed to improve drug delivery for CNS disorders. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of ...

Results: CNS stimulants have psychotropic effects that may be perceived to be ergogenic. Some are prescription drugs, such as Ephedra alkaloids, and there are issues regarding their appropriate ...

NORTH DAKOTA (KXNET) — Marijuana, opioids, and central nervous system stimulants (CNSS) are the most used illegal drugs by ...

Increased risk for CNS adverse events (eg, hallucinations and confusion, cardiac events resulting in falls or other sequelae, drug-drug and drug-disease interactions) in elderly. Only use ...

chief medical officer of CNS Pharmaceuticals, “the fact that this study showed no cardiotoxicity with Berubicin, even in those receiving the drug for over a year, suggests Berubicin could be a ...

Blue Oak has been operating largely under the radar since it was set up in 2016, but has quietly started building alliances as it prepares to advance new drug classes for central nervous system ...

Accordingly, AMPAR and KAINR represent two important glutamate-gated ion channel (GGIC) targets to treat CNS pathologies. Both are clinically validated drug targets for epilepsy, and both are ...